Epiphany Partners is a world-class epidemiology research and consulting group to the pharmaceutical and biotechnology industries. We build and consult on global epidemiology data sets for cancer and related diseases.
The world’s cancer environment changes continually, in light of breakthroughs, trends in data, and treatment development. We continually monitor the environment, in order to incorporate all of this information into our models and analyses.
Epiphany’s founding partners met and worked together at SRI International in Menlo Park, California more than 25 years ago. At the time, they first collaborated on the industry’s original cancer multi-client report, titled, “C3: International Opportunities in Cancer Management.” Peter served as product supervisor, Roger as one of the product designers, and both Roger and Monique devised the report’s cancer epidemiology section.
Over the years, the team continued to improve their patient flow models and detailed cancer and country coverage. First in DaVinci Healthcare Partners, a cancer consultancy focused on solving many of the most challenging problems with current cancer epidemiology data. This in turn became the foundation for Epiphany Partners, evolving to make cancer epidemiology data more accessible and understandable to clients.
Today, Epiphany consults with Fortune 500 companies, multinational research firms, pharmaceutical giants, and biotech innovators. The EpicOncology™ platform sees thousands of queries every month.
The world benefits from EpicOncology™. To us, that’s not only an honor . . . it’s a responsibility.
Epiphany is a member of the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). We support ASCO’s Conquer Cancer Foundation on an annual basis.